0
     

Report Added
Report already added
Urological Cancer Drugs Market - Global Outlook and Forecast 2022-2028

Urological Cancer Drugs Market - Global Outlook and Forecast 2022-2028

This report contains market size and forecasts of Urological Cancer Drugs in global, including the following market information:

Global Urological Cancer Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Urological Cancer Drugs Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Urological Cancer Drugs companies in 2021 (%)
The global Urological Cancer Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Tablets Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Urological Cancer Drugs include Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation and Dendreon Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Urological Cancer Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:
Global Urological Cancer Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Urological Cancer Drugs Market Segment Percentages, by Type, 2021 (%)
Tablets
Injection
Global Urological Cancer Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Urological Cancer Drugs Market Segment Percentages, by Application, 2021 (%)
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Others
Global Urological Cancer Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Urological Cancer Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Urological Cancer Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Urological Cancer Drugs revenues share in global market, 2021 (%)
Key companies Urological Cancer Drugs sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Urological Cancer Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A
Tolmar Inc
Table of Contents

1 Introduction to Research & Analysis Reports
1.1 Urological Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Urological Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Urological Cancer Drugs Overall Market Size
2.1 Global Urological Cancer Drugs Market Size: 2021 VS 2028
2.2 Global Urological Cancer Drugs Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Urological Cancer Drugs Sales: 2017-2028
3 Company Landscape
3.1 Top Urological Cancer Drugs Players in Global Market
3.2 Top Global Urological Cancer Drugs Companies Ranked by Revenue
3.3 Global Urological Cancer Drugs Revenue by Companies
3.4 Global Urological Cancer Drugs Sales by Companies
3.5 Global Urological Cancer Drugs Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Urological Cancer Drugs Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Urological Cancer Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Urological Cancer Drugs Players in Global Market
3.8.1 List of Global Tier 1 Urological Cancer Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Urological Cancer Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Urological Cancer Drugs Market Size Markets, 2021 & 2028
4.1.2 Tablets
4.1.3 Injection
4.2 By Type - Global Urological Cancer Drugs Revenue & Forecasts
4.2.1 By Type - Global Urological Cancer Drugs Revenue, 2017-2022
4.2.2 By Type - Global Urological Cancer Drugs Revenue, 2023-2028
4.2.3 By Type - Global Urological Cancer Drugs Revenue Market Share, 2017-2028
4.3 By Type - Global Urological Cancer Drugs Sales & Forecasts
4.3.1 By Type - Global Urological Cancer Drugs Sales, 2017-2022
4.3.2 By Type - Global Urological Cancer Drugs Sales, 2023-2028
4.3.3 By Type - Global Urological Cancer Drugs Sales Market Share, 2017-2028
4.4 By Type - Global Urological Cancer Drugs Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Urological Cancer Drugs Market Size, 2021 & 2028
5.1.2 Prostate Cancer
5.1.3 Bladder Cancer
5.1.4 Kidney Cancer
5.1.5 Testicular Cancer
5.1.6 Others
5.2 By Application - Global Urological Cancer Drugs Revenue & Forecasts
5.2.1 By Application - Global Urological Cancer Drugs Revenue, 2017-2022
5.2.2 By Application - Global Urological Cancer Drugs Revenue, 2023-2028
5.2.3 By Application - Global Urological Cancer Drugs Revenue Market Share, 2017-2028
5.3 By Application - Global Urological Cancer Drugs Sales & Forecasts
5.3.1 By Application - Global Urological Cancer Drugs Sales, 2017-2022
5.3.2 By Application - Global Urological Cancer Drugs Sales, 2023-2028
5.3.3 By Application - Global Urological Cancer Drugs Sales Market Share, 2017-2028
5.4 By Application - Global Urological Cancer Drugs Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Urological Cancer Drugs Market Size, 2021 & 2028
6.2 By Region - Global Urological Cancer Drugs Revenue & Forecasts
6.2.1 By Region - Global Urological Cancer Drugs Revenue, 2017-2022
6.2.2 By Region - Global Urological Cancer Drugs Revenue, 2023-2028
6.2.3 By Region - Global Urological Cancer Drugs Revenue Market Share, 2017-2028
6.3 By Region - Global Urological Cancer Drugs Sales & Forecasts
6.3.1 By Region - Global Urological Cancer Drugs Sales, 2017-2022
6.3.2 By Region - Global Urological Cancer Drugs Sales, 2023-2028
6.3.3 By Region - Global Urological Cancer Drugs Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Urological Cancer Drugs Revenue, 2017-2028
6.4.2 By Country - North America Urological Cancer Drugs Sales, 2017-2028
6.4.3 US Urological Cancer Drugs Market Size, 2017-2028
6.4.4 Canada Urological Cancer Drugs Market Size, 2017-2028
6.4.5 Mexico Urological Cancer Drugs Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Urological Cancer Drugs Revenue, 2017-2028
6.5.2 By Country - Europe Urological Cancer Drugs Sales, 2017-2028
6.5.3 Germany Urological Cancer Drugs Market Size, 2017-2028
6.5.4 France Urological Cancer Drugs Market Size, 2017-2028
6.5.5 U.K. Urological Cancer Drugs Market Size, 2017-2028
6.5.6 Italy Urological Cancer Drugs Market Size, 2017-2028
6.5.7 Russia Urological Cancer Drugs Market Size, 2017-2028
6.5.8 Nordic Countries Urological Cancer Drugs Market Size, 2017-2028
6.5.9 Benelux Urological Cancer Drugs Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Urological Cancer Drugs Revenue, 2017-2028
6.6.2 By Region - Asia Urological Cancer Drugs Sales, 2017-2028
6.6.3 China Urological Cancer Drugs Market Size, 2017-2028
6.6.4 Japan Urological Cancer Drugs Market Size, 2017-2028
6.6.5 South Korea Urological Cancer Drugs Market Size, 2017-2028
6.6.6 Southeast Asia Urological Cancer Drugs Market Size, 2017-2028
6.6.7 India Urological Cancer Drugs Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Urological Cancer Drugs Revenue, 2017-2028
6.7.2 By Country - South America Urological Cancer Drugs Sales, 2017-2028
6.7.3 Brazil Urological Cancer Drugs Market Size, 2017-2028
6.7.4 Argentina Urological Cancer Drugs Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Urological Cancer Drugs Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Urological Cancer Drugs Sales, 2017-2028
6.8.3 Turkey Urological Cancer Drugs Market Size, 2017-2028
6.8.4 Israel Urological Cancer Drugs Market Size, 2017-2028
6.8.5 Saudi Arabia Urological Cancer Drugs Market Size, 2017-2028
6.8.6 UAE Urological Cancer Drugs Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Novartis
7.1.1 Novartis Corporate Summary
7.1.2 Novartis Business Overview
7.1.3 Novartis Urological Cancer Drugs Major Product Offerings
7.1.4 Novartis Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.1.5 Novartis Key News
7.2 Pfizer
7.2.1 Pfizer Corporate Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Urological Cancer Drugs Major Product Offerings
7.2.4 Pfizer Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.2.5 Pfizer Key News
7.3 Johnson & Johnson
7.3.1 Johnson & Johnson Corporate Summary
7.3.2 Johnson & Johnson Business Overview
7.3.3 Johnson & Johnson Urological Cancer Drugs Major Product Offerings
7.3.4 Johnson & Johnson Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.3.5 Johnson & Johnson Key News
7.4 AstraZeneca
7.4.1 AstraZeneca Corporate Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Urological Cancer Drugs Major Product Offerings
7.4.4 AstraZeneca Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.4.5 AstraZeneca Key News
7.5 Astellas
7.5.1 Astellas Corporate Summary
7.5.2 Astellas Business Overview
7.5.3 Astellas Urological Cancer Drugs Major Product Offerings
7.5.4 Astellas Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.5.5 Astellas Key News
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Corporate Summary
7.6.2 Bristol-Myers Squibb Business Overview
7.6.3 Bristol-Myers Squibb Urological Cancer Drugs Major Product Offerings
7.6.4 Bristol-Myers Squibb Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.6.5 Bristol-Myers Squibb Key News
7.7 Abbott Laboratories
7.7.1 Abbott Laboratories Corporate Summary
7.7.2 Abbott Laboratories Business Overview
7.7.3 Abbott Laboratories Urological Cancer Drugs Major Product Offerings
7.7.4 Abbott Laboratories Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.7.5 Abbott Laboratories Key News
7.8 Celgene Corporation
7.8.1 Celgene Corporation Corporate Summary
7.8.2 Celgene Corporation Business Overview
7.8.3 Celgene Corporation Urological Cancer Drugs Major Product Offerings
7.8.4 Celgene Corporation Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.8.5 Celgene Corporation Key News
7.9 Dendreon Corporation
7.9.1 Dendreon Corporation Corporate Summary
7.9.2 Dendreon Corporation Business Overview
7.9.3 Dendreon Corporation Urological Cancer Drugs Major Product Offerings
7.9.4 Dendreon Corporation Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.9.5 Dendreon Corporation Key News
7.10 Ferring Pharmaceuticals
7.10.1 Ferring Pharmaceuticals Corporate Summary
7.10.2 Ferring Pharmaceuticals Business Overview
7.10.3 Ferring Pharmaceuticals Urological Cancer Drugs Major Product Offerings
7.10.4 Ferring Pharmaceuticals Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.10.5 Ferring Pharmaceuticals Key News
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Corporate Summary
7.11.2 GlaxoSmithKline Urological Cancer Drugs Business Overview
7.11.3 GlaxoSmithKline Urological Cancer Drugs Major Product Offerings
7.11.4 GlaxoSmithKline Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.11.5 GlaxoSmithKline Key News
7.12 Indevus Pharmaceuticals Inc
7.12.1 Indevus Pharmaceuticals Inc Corporate Summary
7.12.2 Indevus Pharmaceuticals Inc Urological Cancer Drugs Business Overview
7.12.3 Indevus Pharmaceuticals Inc Urological Cancer Drugs Major Product Offerings
7.12.4 Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.12.5 Indevus Pharmaceuticals Inc Key News
7.13 Ipsen
7.13.1 Ipsen Corporate Summary
7.13.2 Ipsen Urological Cancer Drugs Business Overview
7.13.3 Ipsen Urological Cancer Drugs Major Product Offerings
7.13.4 Ipsen Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.13.5 Ipsen Key News
7.14 Roche Healthcare
7.14.1 Roche Healthcare Corporate Summary
7.14.2 Roche Healthcare Business Overview
7.14.3 Roche Healthcare Urological Cancer Drugs Major Product Offerings
7.14.4 Roche Healthcare Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.14.5 Roche Healthcare Key News
7.15 Sanofi S.A
7.15.1 Sanofi S.A Corporate Summary
7.15.2 Sanofi S.A Business Overview
7.15.3 Sanofi S.A Urological Cancer Drugs Major Product Offerings
7.15.4 Sanofi S.A Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.15.5 Sanofi S.A Key News
7.16 Tolmar Inc
7.16.1 Tolmar Inc Corporate Summary
7.16.2 Tolmar Inc Business Overview
7.16.3 Tolmar Inc Urological Cancer Drugs Major Product Offerings
7.16.4 Tolmar Inc Urological Cancer Drugs Sales and Revenue in Global (2017-2022)
7.16.5 Tolmar Inc Key News
8 Global Urological Cancer Drugs Production Capacity, Analysis
8.1 Global Urological Cancer Drugs Production Capacity, 2017-2028
8.2 Urological Cancer Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Urological Cancer Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Urological Cancer Drugs Supply Chain Analysis
10.1 Urological Cancer Drugs Industry Value Chain
10.2 Urological Cancer Drugs Upstream Market
10.3 Urological Cancer Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Urological Cancer Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Urological Cancer Drugs in Global Market
Table 2. Top Urological Cancer Drugs Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Urological Cancer Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Urological Cancer Drugs Revenue Share by Companies, 2017-2022
Table 5. Global Urological Cancer Drugs Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Urological Cancer Drugs Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Urological Cancer Drugs Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Urological Cancer Drugs Product Type
Table 9. List of Global Tier 1 Urological Cancer Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Urological Cancer Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Urological Cancer Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Urological Cancer Drugs Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Urological Cancer Drugs Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Urological Cancer Drugs Sales (K Pcs), 2017-2022
Table 15. By Type - Global Urological Cancer Drugs Sales (K Pcs), 2023-2028
Table 16. By Application – Global Urological Cancer Drugs Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Urological Cancer Drugs Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Urological Cancer Drugs Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Urological Cancer Drugs Sales (K Pcs), 2017-2022
Table 20. By Application - Global Urological Cancer Drugs Sales (K Pcs), 2023-2028
Table 21. By Region – Global Urological Cancer Drugs Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Urological Cancer Drugs Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Urological Cancer Drugs Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Urological Cancer Drugs Sales (K Pcs), 2017-2022
Table 25. By Region - Global Urological Cancer Drugs Sales (K Pcs), 2023-2028
Table 26. By Country - North America Urological Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Urological Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Urological Cancer Drugs Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Urological Cancer Drugs Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Urological Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Urological Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Urological Cancer Drugs Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Urological Cancer Drugs Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Urological Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Urological Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Urological Cancer Drugs Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Urological Cancer Drugs Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Urological Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Urological Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Urological Cancer Drugs Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Urological Cancer Drugs Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Urological Cancer Drugs Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Urological Cancer Drugs Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Urological Cancer Drugs Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Urological Cancer Drugs Sales, (K Pcs), 2023-2028
Table 46. Novartis Corporate Summary
Table 47. Novartis Urological Cancer Drugs Product Offerings
Table 48. Novartis Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Pfizer Corporate Summary
Table 50. Pfizer Urological Cancer Drugs Product Offerings
Table 51. Pfizer Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Johnson & Johnson Corporate Summary
Table 53. Johnson & Johnson Urological Cancer Drugs Product Offerings
Table 54. Johnson & Johnson Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. AstraZeneca Corporate Summary
Table 56. AstraZeneca Urological Cancer Drugs Product Offerings
Table 57. AstraZeneca Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Astellas Corporate Summary
Table 59. Astellas Urological Cancer Drugs Product Offerings
Table 60. Astellas Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. Bristol-Myers Squibb Corporate Summary
Table 62. Bristol-Myers Squibb Urological Cancer Drugs Product Offerings
Table 63. Bristol-Myers Squibb Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Abbott Laboratories Corporate Summary
Table 65. Abbott Laboratories Urological Cancer Drugs Product Offerings
Table 66. Abbott Laboratories Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Celgene Corporation Corporate Summary
Table 68. Celgene Corporation Urological Cancer Drugs Product Offerings
Table 69. Celgene Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. Dendreon Corporation Corporate Summary
Table 71. Dendreon Corporation Urological Cancer Drugs Product Offerings
Table 72. Dendreon Corporation Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Ferring Pharmaceuticals Corporate Summary
Table 74. Ferring Pharmaceuticals Urological Cancer Drugs Product Offerings
Table 75. Ferring Pharmaceuticals Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. GlaxoSmithKline Corporate Summary
Table 77. GlaxoSmithKline Urological Cancer Drugs Product Offerings
Table 78. GlaxoSmithKline Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. Indevus Pharmaceuticals Inc Corporate Summary
Table 80. Indevus Pharmaceuticals Inc Urological Cancer Drugs Product Offerings
Table 81. Indevus Pharmaceuticals Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Ipsen Corporate Summary
Table 83. Ipsen Urological Cancer Drugs Product Offerings
Table 84. Ipsen Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Roche Healthcare Corporate Summary
Table 86. Roche Healthcare Urological Cancer Drugs Product Offerings
Table 87. Roche Healthcare Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Sanofi S.A Corporate Summary
Table 89. Sanofi S.A Urological Cancer Drugs Product Offerings
Table 90. Sanofi S.A Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. Tolmar Inc Corporate Summary
Table 92. Tolmar Inc Urological Cancer Drugs Product Offerings
Table 93. Tolmar Inc Urological Cancer Drugs Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 94. Urological Cancer Drugs Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 95. Global Urological Cancer Drugs Capacity Market Share of Key Manufacturers, 2020-2022
Table 96. Global Urological Cancer Drugs Production by Region, 2017-2022 (K Pcs)
Table 97. Global Urological Cancer Drugs Production by Region, 2023-2028 (K Pcs)
Table 98. Urological Cancer Drugs Market Opportunities & Trends in Global Market
Table 99. Urological Cancer Drugs Market Drivers in Global Market
Table 100. Urological Cancer Drugs Market Restraints in Global Market
Table 101. Urological Cancer Drugs Raw Materials
Table 102. Urological Cancer Drugs Raw Materials Suppliers in Global Market
Table 103. Typical Urological Cancer Drugs Downstream
Table 104. Urological Cancer Drugs Downstream Clients in Global Market
Table 105. Urological Cancer Drugs Distributors and Sales Agents in Global Market

List of Figures
Figure 1. Urological Cancer Drugs Segment by Type
Figure 2. Urological Cancer Drugs Segment by Application
Figure 3. Global Urological Cancer Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Urological Cancer Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Urological Cancer Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. Urological Cancer Drugs Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Urological Cancer Drugs Revenue in 2021
Figure 9. By Type - Global Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 10. By Type - Global Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 11. By Type - Global Urological Cancer Drugs Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 13. By Application - Global Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 14. By Application - Global Urological Cancer Drugs Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 16. By Region - Global Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 17. By Country - North America Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 18. By Country - North America Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 19. US Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 24. Germany Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. France Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 33. China Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. India Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 39. By Country - South America Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 40. Brazil Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Urological Cancer Drugs Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Urological Cancer Drugs Sales Market Share, 2017-2028
Figure 44. Turkey Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Urological Cancer Drugs Revenue, (US$, Mn), 2017-2028
Figure 48. Global Urological Cancer Drugs Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Urological Cancer Drugs by Region, 2021 VS 2028
Figure 50. Urological Cancer Drugs Industry Value Chain
Figure 51. Marketing Channels

Report Title: Urological Cancer Drugs Market - Global Outlook and Forecast 2022-2028


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update